FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, particularly to pharmacology and pharmaceutics, and concerns a pharmaceutical composition containing a therapeutically effective amount of N-(2-adamantyl)-hexamethylenimine hydrochloride (hymatan) as an active ingredient, and excipients - starch, lactose, microcrystalline cellulose (MCC), aerosil, ludipress, twice-substituted calcium phosphate, polyvinylpyrrolidone, methylcellulose, carboxymethyl cellulose and its sodium salt, oxypropylcellulose, oxpropylmethylcellulose, mannitol, sorbite, stearic acid and/or its salts and other excipients. The composition is presented as solid dosage forms.
EFFECT: dosage forms easily release the active ingredient that enables its high bioavailability; the solid dosage forms provides a manifested antiparkinsonian action when administered in the patients suffering Parkinson's disease.
14 cl, 3 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INJECTABLE DOSAGE FORM FOR TREATMENT OF PARKINSON'S DISEASE, METHOD FOR PREPARING AND USING IT | 2011 |
|
RU2520758C2 |
| PHARMACEUTICAL COMPOSITION IN GEL MEDICINAL FORM FOR LOCAL USE ON THE BASIS OF N-(2-ADAMANTIL)-HEXAMETHYLENEMINE HYDROCHLORIDE | 2017 |
|
RU2663452C1 |
| MEDICATION FOR TREATING CEREBRAL CIRCULATION DISORDERS AND BRAIN TRAUMAS | 2012 |
|
RU2554502C9 |
| USING HEPTAPEPTIDE FOR TREATING PARKINSON'S DISEASE AND METHOD OF TREATING SUCH DISEASE | 2011 |
|
RU2450822C1 |
| METHOD FOR CURATIVE EFFECT ON PATIENT BODY IN TREATMENT OF PARKINSON'S DISEASE | 2002 |
|
RU2213565C1 |
| PARKINSON'S DISEASE TREATMENT MODE | 2007 |
|
RU2353382C1 |
| IMPROVED TRANSCUTANEOUS THERAPY SYSTEM FOR TREATING PARKINSON DISEASE CASES | 2002 |
|
RU2273477C2 |
| METHOD OF REHABILITATION OF PATIENTS WITH PARKINSON'S DISEASE | 2010 |
|
RU2436557C1 |
| ADAMANTYL DERIVATIVES OF BENZIMIDAZOLE, HAVING ANTIPARKINSONIAN ACTIVITY | 2023 |
|
RU2820315C1 |
| DIAGNOSTIC METHOD OF POSTURAL DISORDERS IN PARKINSON'S DISEASE | 2020 |
|
RU2733037C1 |
